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Review Article 
Inflammatory bowel disease:clinical features and manifestations beyond the bowel 
 
 
Abstract. Inflammatory bowel disease(IBD)encompassesaspectrumof diseases, withCrohn’s 
disease(CD)andulcerativecolitis(UC) representing the two broadest subtypes of IBD. Multiple 
extraintestinal manifestations (EIMs) are more frequent in (IBD); 5% –50% of the patients might 
be affected. The most often implicated sites of manifestations are musculoskeletal and 
dermatological structures.However,while some symptoms like peripheral arthritis and erythema 
nodosum correlate with IBD progression, others have their own course of disease like axial 
arthropathy, gangrenosis of the pioderma and primary sclerosic cholangitis. This review would 
provide a summary of the most frequent EIMs and their prevalence. 
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1. Introduction  
Inflammatory bowel disease (IBD) is a chronic diseasewhich relapses immune-mediated. 
The two major IBD subtypes are ulcerative colitis and Crohn's disease 
1
.Ulcerative colitis is a 
chronic, idiopathic inflammatory condition that affects the colon, most frequently affecting 
adults between 30 and 40 years of age with disabilities 
2, 3
 .It is characterized by relapse and 
remittance of inflammation in mucosal tissues, starting in the rectum and spreading to proximal 
colon segments.UC marked by cycles of recovery and cycles of recurrent, the latter, frequently 
presenting with a combination of abdominal pain vomiting, rectal bleeding,weight lossand 
malaise, is responsible for the vast majority of the disease burden and reduced quality of life 
4, 5
.  
The risk for UC newly diagnosed patients is between 10% and 35% for five years and 
ultimately the long-term risk of colorectal cancer is enhanced by extensive and persistent 
inflammatory activity 
6
. The control of symptoms such as increased frequency of bowel 
movement and rectal hemorrhage was a controlled problem
5
. The introduction of standardized 
clinical scores, such as the Truelove and Witts criteria
7
 and the Mayo score
5
, allowed for a more 
accurate evaluation of the disease and, while they are sometimes used in clinical trials
8, 9
, have 
not yet been validated. This strategy, aimed at regulating and alleviating the effects of 
inflammation, did not target the inflammatory activity itself.  
In comparison, there is a major correlation between clinical IBD and other disorders, 
such as irritable bowel syndrome (IBS) or infectious diarrhea 
10
, And some authors recorded a 
long-term recovery of UC patients with IBS-like symptoms (abdominal pain, elevated stool 
frequency) two to three times more frequency than controls 
14
. In contrast, others observed high 
stool frequency in up to 27% of patients with full endoscopic and histological healing, indicating 
a potential explanation for non-inflammatory functional intestinal damage 
15
. Finally, in a 
systematic study of clinical trials, clinical recovery during the placebo reached up to 15% 
16
. 
However, there is growing evidence that clinical improvement without mucosal healing (MH) is 
  
not associated with reduced hospitalization or colectomy rates over the years 
17, 18
.Inflammatory 
markers such as erythrocyte sedimentation rate, fecal marker calprotectin  and serum markers C-
reactive protein are other desirable choices for tracking UC patients
11
. 
 Further studies are required to explain adequate surveillance strategies and cut-off rates 
before it is widely used in clinical practice.Mucosal inflammation is a central component of both 
UC and CD but, unlike Crohn's disease, a transmural disease with both strict and penetrating 
phenotypes, the development of the disease is limited to the UC mucosa 
12
. Therefore, it is no 
surprise that MH will prove an appealing target when addressing UC patients regardless of the 
severity of the disorder, inflammatory biomarkers or clinical presentation. Extensive research has 
been published over the past decade supporting the value of histological healing
13, 14
as it has 
shown excellent correlation with reduced risk of relapse
15
and hospitalization 
16
. In some studies, 
histological healing may be involved in the definition of MH in addition to the endoscopic 
findings 
16
. 
The therapy is aimed at inducing and sustaining clinical and endoscopic 
remission.Current treatment choice for UC includes  aminosalicylates, such as corticosteroids 
(including systemic corticosteroids such as hydrocortisone or prednisolone, and topical 
corticosteroids such as budesonide), mesalamine (5-aminosalicylic acid; 5-ASA) in both oral and 
rectal formulations, sulfasalazine,thiopurines (6-mercaptopurine and azathioprine), calcineurin 
inhibitors (tacrolimus and cyclosporine),  anti-tumor necrosis factor (TNF)-a drugs (including 
infliximab, adalimumab, and golimumab), methotrexate andmore recently, the anti-integrin drug 
vedolizumab
16
.This review summarizesthe most common EIMs and itsclinical features and their 
prevalence and suggested management 
2. Extraintestinal manifestations 
UC and CD also cause extraintestinal manifestations (Table. 1), as seen in 25 to 40 % of 
patients with IBD 
45
. Almost every organ may be affected, but the primary manifestations are 
symptoms affecting the skin, eyes, joints and liver. Having one extraintestinal manifestation 
raises the likelihood that another will develop 
46
.  
The treatment of underlying gut inflammation leads to the symptoms of concurrent 
disease activity such as erythema nodosum, episcleritis peripheral and arthritis. IBD can be 
associated with a specific disease, for example, IBD is closely correlated with primary sclerosing 
cholangitis (PSC); 75% of PSC patients have UC and 5 %to 10 % have CD. Nevertheless, only 5% 
of UC patients and 2% of CD patients develop PSC, respectively. 
47
. IBD patients are suffering 
from persistent diarrhea, usually with mucous and blood. For UC, symptom period may vary and 
appear to be more indolent, lasting weeks to months 
17-19
. 
Extraintestinal manifestations in 21% -47% of patients with IBD are reported.
1
. Most 
extraintestinal manifestations are not well known for pathogenesis. In recent years, however, 
significant advances in the genetic basis of IBD have occurred with the advent of genomewide 
interaction studies. In particular, 99 susceptibility loci or genes have been reported to date (47 in 
ulcerative colitis and 71 in Crohn's disease)
20
.  
Many organs may be involved withextraintestinal manifestations in IBD patients. 
Extraintestinal symptoms injoints,skin, hair have been correlated with the level of bowel 
  
inflammation, but cardiothoracic and gastrointestinal (hepatobiliary) desorption generally did 
nothave that correlation. 
1
.  
2.1 IBD Manifestations of gastrointestinal  
Pancreatic and hepatobiliary damageconsider the most severe extraintestinal 
manifestationsin IBD patients. While the relations between many liver disorders and IBD are 
well known, other associations are far more.
21
. 
2.1.1 Primary Sclerosing Cholangitis  
In the IBD setting, PSC is the most common hepatobiliary manifestation 
20
. PSC 
symptoms are progressive inflammation in the biliary tree, obliterative fibrosis and death, 
resulting in biliary fibrosis, cirrhosis and probable hepatic failure
22
. The PSC-IBD relationship 
was first identified by Smith and Loe in 1965
23
. 
 
 
 
 
 
 
 
Table 1. Extraintestinal Manifestations of IBD 
 
 
 
 
 
Gastrointestinal  
 
Primary sclerosing cholangitis (PSC) 
PSC–autoimmune “hepatitis overlap syndrome” 
Drug-induced hepatitis  
Hepatic steatosis 
Hepatic abscess 
Portal vein thrombosis 
Pancreatitis 
Immunoglobulin G4 (IgG4)–associated 
cholangitis 
Primary biliary cirrhosis 
Cholelithiasis 
Autoimmune pancreatitis 
 
Urinary 
Enterourinary fistulas 
Obstructive uropathy 
Nephrolithiasis 
Musculoskeletal Arthritis: ankylosing spondylitis, isolated joint involvement 
Hypertrophic osteoarthropathy: clubbing, periostitis 
Other: aseptic necrosis, polymyositis 
Pulmonary Large airways disease 
Pneumonia 
  
 
2.1.2 PSC–Autoimmune (Hepatitis Overlap Syndrome) 
In IBD patients, especially in ulcerative colitis patients, an association between 
autoimmune hepatitis and PSC has been reported. Several case reports of IBD patients who were 
initially diagnosed with autoimmune hepatitis later established PSC histological evidence 
24
. 
2.1.3 Cholangiocarcinoma  
The emergence ofcholangiocarcinoma, a crippling malignancy with an exceedingly poor 
prognosis, is a feared complication of PSC. Though cholangiocarcinoma does not result directly 
from IBD, the literature has well established a significantrelation between cholangiocarcinoma 
and PSC 
1
.PSC patients tend to show cholangiocarcinoma earlier than intermittent 
cholangiocarcinoma
25
.With a lifetime incidence of 5%-15%, PSC patients have a  substantially 
higher chance of cholangiocarcinoma progress
26
. 
2.1.4 Drug-induced Hepatitis  
Although hepatobiliary disorders described above share common IBD pathogenesis; 
many medicines used to treat IBD can cause liver toxicity. A variety of medications have been 
involved, includingsulfasalazine,cyclosporine, thiopurines,methotrexate as well as 
certolizumab,adalimumab and infliximabas the biologic agents. Influenza-like symptoms 
andincreased liver enzymesin hepatotoxicity conditionusually resolve after the drug treatment 
has been discontinued 
27.  
2.1.5 Hepatic Steatosis  
The most hepatobiliary complication of IBD is hepatic steatosis, or fatty liver
28
. Agroup 
of researchers reported that 35% of the 511 IBD patients had a fatty liver disorder
29
. In published 
studies,fatty liver  disease has beenshown amassive variability in its prevalence (13% to 100%) 
1
. 
The level of fatty liver infiltration and the severity of colitis were found to be associated with 
Cardiac Congestive heart failure 
 
 
Ocular system 
 
Uveitis/iritis, episcleritis, scleromalacia, corneal ulcers, retinalvascular disease 
Conjunctivitis 
Orbital pseudotumor 
 
Dermatologic/Oral 
system 
 Reactive lesions: erythema nodosum, pyoderma gangrenosum, 
aphthous ulcers, necrotizing vasculitis 
 Specific lesions: fissures, fistulas, oral Crohn disease, drug rashes 
 Nutritional deficiencies: acrodermatitis enteropathica, purpura,glossitis, hair loss, brittle nails 
 Associated diseases: vitiligo, psoriasis, amyloidosis 
 
Hematologic 
 
Anemia, hyperhomocysteinemia 
 
Metabolic system 
 
Growth retardation in children and adolescents, delayed sexual maturation, 
osteopenia/osteoporosis 
  
ulcerative colitis patients.
30
. In IBD patients, the protein deficiency, corticosteroid therapy and 
chronic malnutrition, may lead fatty liver condition whilethe exact causesare somewhat unclear, 
1
. 
2.1.6 Hepatic Abscess  
The frequency of pyogenic liver abscesses in patients with IBD is slightly greater than in 
the general population
28
. Researchers indicated that the loss of barrier integrity of the intestine 
mucosamay lead toliver damage by an infectious agent through mesenteric veins
1
. In addition, 
portal vein associated- thrombosis can alsooccur in the portal pyelophlebitis condition
31
. 
2.1.7 Portal vein thrombosis  
In IBD patients, a thrombosis disorder is commonly observed at the portal vein 
28
.The 
levels of platelets, fibrinogen and factor V and VIII have been increased in patients with IBD, 
with antithrombin III being lowered, both of which may raise the risk of thrombosis.  The  IBD 
patients who have just undergone abdominal surgeryare more likely to develop portal vein 
thrombosis
32
. In patients with ulcerative colitis following restorative proctocolectomy, the portal 
vein thrombosis with a high incidence has been recorded  
33
. 
2.1.8 IBD and Pancreatic manifestations  
Concerning IBD-associatedpancreatic manifestationsin autopsies, in 1950, Ball et al. 
34
receded on pancreatic features accompanied by UC detected for the first time. In 1956, Chapin 
et al. 
35
described that histological changes in the pancreas with regional enteritis were mainly 
interlobar and periductal fibrosis and swelling of the acinar cells
36
.Subsequently, in US and 
Europe, researches on IBD, especially pancreatitis associated CD, have been recorded 
progressively since the 1970s
37-39
. 
Pancreatic disorders related with IBD involve, pancreatic cancer (PC) acute pancreatitis 
(AP), chronic pancreatitis (CP), increasing of pancreatic enzymesandexocrine pancreatic 
insufficiency (EPI
40
.More details about pancreatic manifestations accompanied by IBDis shown 
inFig. 1. 
  
 
 
Figure 1. Pancreatic manifestations accompanied by IBD. 
 
2.1.9 Other diseases associated with IBD 
IgG4-associated cholangitis. It was identified in individuals with diseasesassociated 
with IgG4with autoimmune pancreatitis, a relation between ulcerative colitis and cholangitis 
associated with IgG4 has beenobserved
41
. 
Primary biliary cirrhosis. It is a characteristic autoimmune disorder of the hepatic tissue 
that arises through the progressive degradation of the inflammatory bile ducts and the 
obliteration of plasma cells and lymphocytes toward the portal way. The literature indicates a 
correlation between IBD and primary biliary cirrhosis but has not yet been widely recognized 
42
. 
Cholelithiasis. Gallstones are commonly found in IBD patients. IBD progression and its 
pathophysiological changes may lead to gallstone development. A substantial correlation has 
been identified between cholelithiasis abnormality and Crohn's disease, with 13% and 34% as a 
prevalence rate
43
. The link between ulcerative colitis and cholelithiasis is uncertain, because, in 
ulcerative colitis patients,there does not seem to be a substantially elevated incidence of 
gallstones relative to the general population
29
. 
Autoimmune Pancreatitis.A correlation between autoimmune pancreatitisand IBD have 
proposed by some researchers, while to date, the preciseassociation is not well-defined. It has 
been shown that IBD-associated pancreatitis has similar clinical, morphological, and histological 
characteristics to the same detected featuresin autoimmune pancreatitis
43
.  
3. Urinary manifestations of IBD 
In the IBD setting, the majority ofdifferent urinary complications have been reported in 
patients with Crohn's disease, with an incidence rate of 4% -23%.The complications are clearly 
  
appearing in people with serious or chronic illness. Urinary conditions can be directly or 
indirectly associated with the development of the disease
44
.  
3.1 Enterourinary Fistulas  
These disorders are the most comfortable urinary form inpatientswithIBD, a colovesical 
fistulas are the famous type of fistula. While,in Crohn's disease,gastrointestinal tract-confined 
fistulas are relatively common, fistulas between the urinary system and the gastrointestinal tract 
are much less common and severe complications, with an incidence rate of 2%-3.5% 
44
. Most 
patients with a well-known history of IBD are in their 4th or 5th decade. The incidence rate is 
high in males, due to the position of the adnexa and uterus in women between the intestines and 
the bladder
45
.  
3.2 Obstructive Uropathy  
Calculus obstructive uropathy is occurring in 1.9% – 6% of Crohn disease patients, is 
oftenignored urologic complication of Crohn disease 
44
. Transmural bowel inflammation may 
lead to hydroureteronephrosis which followed by ureteral compression, fibrosis, or encasement 
and the right collecting ductsusually involved. 
46
. 
3.3 Nephrolithiasis 
IBD patients are 10–100 times more susceptiblethan other patients inthe hospital to 
develop nephrolithiasis, with 12 % as an incidence rate in patients withCrohn's disease 
44
. Adults 
with Crohn's disease are at higher risk relative to patients with ulcerative colitis than children
47
. 
4. IBD and musculoskeletal manifestations  
There are multiple musculoskeletal forms of IBD;almost 53% of patients have 
musculoskeletal system-related pain
48
.The most common sites involved in IBD arthropathy are 
axial and peripheral
49
. 
4.1 IBD-related Spondyloarthropathy  
This disease involves psoriatic arthritis, idiopathic ankylosing spondylitis, 
undifferentiated spondyloarthropathyand reactive arthritis. Spondyloarthropathy associated with 
IBD is divided into peripheral and axial arthropathy. Symptoms of axial type include back pain, 
sacroiliitis that triggers inflammation and spondylitis, whereas peripheral arthritis includes self-
limiting nondeforming arthritis which develops and decreases with intestinal flares 
50
. 
4.2 IBD and arthropathy manifestations 
Arthropathy is common among IBD patients, and this condition is known as 
spondylarthritis (SpA).The SpA is further graded, based on the primary signs, as axial and 
peripheral
51
. A diagnosis of axial SpA is made using sacroiliitis radiographic findings consistent 
with symptoms of low back inflammatory pain. Radiological findings of sacroiliitis are 
significant in about 15%-27% of IBD patients,
52-54
while, progressive ankylosing spondylitis (AS) 
  
with syndesmophytes occurs in only about 3%-10% of patients.In addition, in Crohn's disease 
(CD) and AS patients, HLA‐B27 is found in approximately 25%–75% of cases, whereas in those 
with isolated sacroiliitis, HLA‐B27 is found in only 7%–15% of cases. HLA‐B27 Positivity in 
IBD patients suggests that these patients are at a higher risk of developing AS;
55
however, since 
HLA‐B27 positivity in idiopathic AS patients is significantly lower, it cannot be regarded as a 
diagnostic marker 
52, 56
. 
5. IBD and pulmonarymanifestations 
Black et al.
57
, in their analysis of population research, found that patients with IBD have 
pulmonary symptoms more often than the general population. Raj et al.
58
observed a four-fold 
rise in the incidence of IBD in their patients with airway disease in a 10-year retrospective study. 
The prevalence of disease-related pulmonary symptoms is highly variable and the symptoms 
continuum is broad. The pathogenesis of pulmonary findings associated with IBD is uncertain, 
but may be associated with an embryological origin of the intestinal mucosa and respiratory, a 
reaction with intestinal epithelium and lung antigen exposure, and/or an  intestinal inflammatory 
mediator 
59
. 
6. IBD and cardiac manifestations  
To date, the link between cardiovascular disorders and IBD has not been completely 
explained. Researchers have indicated that patients with IBD have a higher risk of 
stroke,myocardial infarctionand cardiovascular mortality in recent years, particularly during the 
active stageof the disease. 
60
. The findings of Danish nationwide cohort studyrecorded high 
incidence of heart failure in patients with IBD that was highly associated with active bowel 
disease periods
61
. Other studies have proposed, however, that there is no correlation between 
increased cardiovascular disease incidence andIBD. Furthermore, a meta-analysis of 11 trials 
showed no increase in mortality ofcardiovascular patients between the control group the and IBD 
group 
62
. 
7. IBD and ocular systemmanifestations  
According to the findings ofthe population studyin the  IBD setting,researchers have 
reported that the prevalence of ocular extraintestinal symptoms is between 4 % and 12 %
63
. The 
most common eye findings include inflammatory disorders affecting various areas of the globe, 
ranging from episcleritisandconjunctivitis  to more serious conditions such as anterior uveitis and 
scleritis 
64
. Vision may be permanently compromised with scleritis, or anterior uveitis, while it is 
possible to detect unusual orbital extraintestinal manifestations of IBD with images
59
. 
8. IBD Skin diseases manifestations 
8.1 Erythema nodosum (EN) 
EN is distinguished by the appearance of subcutaneous nodules raised, tender, purple, or 
violet (1–5 cm in diameter), which makes it simple to diagnose. The extensor surface of the 
extremities, particularly the anterior tibial areas, are the most commonly affected areas, and 
occasionally, the trunk or upper extremities are also involved. Also, EN is associated with other 
  
systemic symptoms such as arthralgia and fatigue. This can be clinically treated by removing the 
metastatic CD, and usually no biopsy is performed. 
EN is the most common dermatological manifestation in patients with IBD and is more 
frequent in women and CD patients (4%-15% CD vs. 3%-10% CD cases).
65, 66
.EN is associated 
with IBD activity and flares in general but not with its severity
67
.Because of its connection with 
disease operation, management of the underlying IBD is the cornerstone of therapy. However, 
treatment with systemic corticosteroids may be needed in extreme cases, while treatment with 
infliximab, azathioprine or adalimumab may be required in resistant cases or those with repeated 
relapses
68, 69
. 
8.2Pyoderma gangrenosum 
PG is characterized by the formation of a skin pustule that quickly becomes a violent-
edged burrowing ulcer, around 2–20 cm in diameter. PG occurs most often on the shins and 
adjacent to the stomas, though it can occur anywhere on the body, including genitals.It initially 
occurs as a single or multiple erythematous papule(s)/pustule(s), but subsequent dermis necrosis 
contributes to the production of deep excavating chronic ulcerations. 
For PG, the histopathological findings are non-specific, and hence their diagnosis is made 
dependent on the characteristic findings of the lesions after excluding other possible skin 
diseasesbased on the typical findings of the lesions. In some cases, a biopsy from the periphery 
of the lesion may be required to exclude specific skindiseases. Therefore, a high index of 
suspicion is requiredto avoid misdiagnosis of PG
55
. 
 
CONCLUSIONS 
EIMs are moderately common through the IBD course not only limited to the gut,and in some 
cases, these EIM can be much more crippling than intestinal disease, which can occur long 
before IBD is diagnosed. Careful screening for EIMs in these patients and early appropriate 
diagnosis are imperative to reduce the overall morbidity. Increasing evidence suggests that IBD 
and associated extraintestinal disorders are not isolated diseases but share common mechanistic 
and pathophysiologic pathways, many of which remain elusive to date. In numerous cases, 
controlling the IBDactivity can also help in limiting the EIM; however, the further controlled 
trials remain the keys to development of the early differentiated diagnosis approach and 
promising treatment policies. 
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